Minimal residual disease positivity in acute lymphoblastic leukemia is a major risk factor for relapse and poor outcomes
We evaluated the impact of minimal residual disease levels before allogeneic hematopoietic stem cell transplantation on outcomes for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia
Patients with measurable levels of minimal residual disease have a higher risk of relapse
Achieving minimal residual disease negativity should be a prerequisite for successful allogeneic hematopoietic stem cell transplantation